Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

RCAS1 decidual immunoreactivity in severe pre-eclampsia: immune cell presence and activity.

Authors: Wicherek, L  Basta, P  Sikora, J  Galazka, K  Rytlewski, K  Grabiec, M  Lazar, A  Kalinka, J 
Citation: Wicherek L, etal., Am J Reprod Immunol. 2007 Oct;58(4):358-66.
Pubmed: (View Article at PubMed) PMID:17845206
DOI: Full-text: DOI:10.1111/j.1600-0897.2007.00521.x

PROBLEM: Pre-eclampsia seems to be related to the disturbance of immune tolerance regulation during pregnancy. Receptor-binding cancer antigen expressed on SiSo cells (RCAS1) decidual level alterations were concomitant with changes in immune cell number and activity in decidua. As decidual immunomodulating activity participates in the development of immune tolerance during pregnancy, we aimed to evaluate the immunoreactivity level of decidual RCAS1 with respect to the presence and activity of immune cells. METHOD OF STUDY: RCAS1, CD3, CD56, CD69, and CD25 immunoreactivity was assessed by immunohistochemistry in 30 decidual samples derived from patients with severe pre-eclampsia (sPE) and from a healthy control group. RESULTS: RCAS1 immunoreactivity was statistically significantly higher in decidual tissue samples derived from patients with sPE tissue than in those derived from healthy patients in whom elective cesarean section at term was performed. A statistically significantly lower number of CD56(+) and CD3(+) cells and lower immunoreactivity level of CD69 were found in patients with sPE compared with those from the control group. CONCLUSION: The limited immune cells infiltration in decidua during sPE is associated with increase in RCAS1 decidual level.

Annotation

Disease Annotations
Objects Annotated

Additional Information

 
RGD Object Information
RGD ID: 2289846
Created: 2008-02-14
Species: All species
Last Modified: 2008-02-14
Status: ACTIVE



NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.